IRIS
GALLUZZO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.478
AS - Asia 3.299
EU - Europa 2.007
SA - Sud America 419
AF - Africa 48
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 19.262
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.361
SG - Singapore 1.546
IT - Italia 546
CN - Cina 481
RU - Federazione Russa 360
HK - Hong Kong 339
BR - Brasile 338
BD - Bangladesh 308
VN - Vietnam 243
IE - Irlanda 238
DE - Germania 205
FR - Francia 131
GB - Regno Unito 109
JP - Giappone 108
FI - Finlandia 95
IN - India 73
UA - Ucraina 72
CA - Canada 69
NL - Olanda 53
SE - Svezia 46
ID - Indonesia 42
KR - Corea 34
AR - Argentina 32
PL - Polonia 32
ES - Italia 29
AT - Austria 28
MX - Messico 19
CO - Colombia 18
PK - Pakistan 17
TR - Turchia 16
ZA - Sudafrica 16
CH - Svizzera 13
IQ - Iraq 12
EC - Ecuador 9
MA - Marocco 9
MY - Malesia 9
PH - Filippine 9
PY - Paraguay 9
CL - Cile 8
LT - Lituania 7
NP - Nepal 7
PT - Portogallo 7
UZ - Uzbekistan 7
AU - Australia 6
BE - Belgio 6
JM - Giamaica 6
RO - Romania 6
GR - Grecia 5
IR - Iran 5
KG - Kirghizistan 5
SA - Arabia Saudita 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
KE - Kenya 4
KZ - Kazakistan 4
TN - Tunisia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CR - Costa Rica 3
EG - Egitto 3
EU - Europa 3
GT - Guatemala 3
HN - Honduras 3
IL - Israele 3
LB - Libano 3
MN - Mongolia 3
PA - Panama 3
SI - Slovenia 3
TH - Thailandia 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BA - Bosnia-Erzegovina 2
ET - Etiopia 2
GE - Georgia 2
JO - Giordania 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AW - Aruba 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BZ - Belize 1
CG - Congo 1
CU - Cuba 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
HR - Croazia 1
HU - Ungheria 1
KY - Cayman, isole 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PS - Palestinian Territory 1
Totale 19.257
Salva come PNG Salva come JPEG
Città #
Wilmington 3.185
Houston 2.944
Woodbridge 1.607
Singapore 757
Fairfield 687
Ashburn 605
San Jose 444
Hong Kong 335
Seattle 334
Chandler 302
Council Bluffs 295
Cambridge 255
Dublin 219
Ann Arbor 191
Dallas 175
Beijing 163
The Dalles 158
Medford 152
Santa Clara 131
Rome 107
New York 103
Los Angeles 97
Tokyo 95
Dearborn 93
Ho Chi Minh City 81
Lawrence 72
Munich 67
Buffalo 65
Hanoi 65
Lauterbourg 63
Moscow 58
San Diego 54
Jacksonville 45
Milan 43
Helsinki 39
Redondo Beach 36
Lappeenranta 34
Nuremberg 33
Jakarta 31
São Paulo 30
London 29
Chennai 28
Toronto 24
Chicago 22
Del Norte 21
Orem 21
Zhengzhou 21
Montreal 20
Seoul 20
Salt Lake City 19
Menlo Park 18
North Bergen 18
Boardman 17
Brooklyn 17
Perugia 17
Naples 16
Redwood City 16
Frankfurt am Main 15
Warsaw 15
Atlanta 14
Colorado Springs 14
Vienna 14
Boston 13
Charlotte 13
Esslingen am Neckar 13
Hyderabad 13
Kraków 13
Shanghai 13
Denver 12
Johannesburg 12
Phoenix 11
Bologna 10
Falls Church 10
Guangzhou 10
Manchester 10
Amsterdam 9
Pune 9
Saint Petersburg 9
San Francisco 9
Turku 9
Ankara 8
Da Nang 8
Genoa 8
Haiphong 8
Stockholm 8
Turin 8
Asunción 7
Engelhard 7
Mexico City 7
Poplar 7
Porto Alegre 7
Bari 6
Brussels 6
Columbus 6
Goiânia 6
Guiyang 6
Kilburn 6
Lahore 6
Montjovet 6
Norwalk 6
Totale 15.001
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 534
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 460
Brodalumab for the treatment of psoriasis 439
Tildrakizumab for treating psoriasis 424
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 421
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 413
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 407
Tofacitinib for the treatment of psoriasis 402
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 402
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 399
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 395
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 378
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 372
A safety evaluation of guselkumab for the treatment of psoriasis 372
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 371
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 355
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 349
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 345
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 342
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 327
Photo-recall cutaneous reaction to gemcitabine 324
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 313
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 300
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 297
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 290
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 286
Pharmacotherapeutic management of psoriasis in adolescents and children 271
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 267
Skin immunity and its dysregulation in psoriasis 262
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 260
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 256
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 246
Successful treatment of psoriatic crumbly nails with ustekinumab 244
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 239
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 223
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 222
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 218
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 202
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 200
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 198
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 158
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 141
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 141
Italian guidelines in diagnosis and treatment of alopecia areata 134
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 133
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 131
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 130
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 124
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) 122
Effectiveness of brodalumab for the treatment of moderate-to-severe psoriasis: a retrospective, real-world multicenter study with a focus on obese and multi-failure patients—IL PSO (Italian Landscape Psoriasis) 122
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 121
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 120
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 112
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 111
A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients 110
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 110
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 109
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 107
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 107
A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study 103
Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series 102
Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis 98
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 97
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 96
BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis) 94
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 94
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 94
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 92
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 88
Quality of life and psychological impact in patients with atopic dermatitis 88
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 86
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 86
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 86
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 85
Linear psoriasis following the typical distribution of the sciatic nerve 85
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 84
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 82
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 82
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 81
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study–IL PSO (Italian Landscape Psoriasis) 80
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 79
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 79
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 79
Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study 78
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 77
Anti-Herpes zoster vaccination in patients with dermatologic diseases: a position statement from the Italian SIDeMaST group of sexually transmitted, infectious and tropical diseases 75
Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study 75
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 74
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 73
Eczematous liraglutide eruption managed by dupilumab: A case report 73
successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: a case series 71
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 71
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 71
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 71
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 70
A microarray-based IgE-molecular mimicry index (IgE-MMI): A biomarker for disease severity, clinical phenotypes, and therapeutic response in atopic dermatitis? 70
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study 69
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 68
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 67
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 66
Totale 18.707
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.597
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022861 46 69 81 14 31 35 140 34 60 52 73 226
2022/2023807 101 81 69 61 55 207 68 32 57 22 30 24
2023/2024565 33 6 15 16 45 80 93 51 3 40 120 63
2024/20252.543 101 412 246 266 49 279 108 119 238 198 315 212
2025/20264.841 293 158 578 254 359 152 627 526 552 510 369 463
2026/2027197 197 0 0 0 0 0 0 0 0 0 0 0
Totale 19.950